Reminder: Corporate Access – Events: Barclays Hosted: Events at ASCO 2026

Research evidence excerpt

Reminder: Corporate Access – Events: Barclays Hosted: Events at ASCO 2026

in a lab using genomic and nongenomic pathology platforms to study the effects between

cancer therapeutics and the immune system. His research has been presented at the San

Antonio Breast Cancer Symposium—an international symposium focused on the treatment

of breast cancer—in addition to presentations at the American Association for Cancer

Research (AACR), the American Society of Clinical Oncology, the Society for Immunology of

Cancer, and at the Eastern Cooperative Oncology Group–American College of Radiology

Imaging Network Cancer Research Group meeting, as well as published in peer reviewed

journals.

Joshua K. Sabari, MD is an Assistant Professor of Medicine, Thoracic Medical Oncologist

and member of the Phase I Experimental Therapeutics Group in the Department of Medical

Oncology at New York University School of Medicine, NYU Langone Health Perlmutter

Cancer Center. He specializes in lung cancers, including non-small cell lung cancer and

small cell lung cancer. His research focuses on developing new treatments for people with

lung cancers. His goal is to develop biomarker-driven clinical trials that offer patients

unprecedented access to novel therapies and personalized treatments. He aims to better

understand why people develop cancer and to create innovative ways to harness the

body’s immune system to fight cancer. He specializes in lung cancer, non-small cell lung

cancer, small cell lung cancer, adenoid cystic carcinoma of the lung, lung carcinoma,

mediastinal tumor, mesothelioma, mucoepidermoid carcinoma of the lung,

neuroendocrine tumor of the lung, thoracic cancer, thymus cancer.

Meet the Analysts

Emily Field, CFA is a Director and Head of U.S.